Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.77 |
| ▸ | NPY1R | P25929 | 14/20 | 0.69 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015353 | 0.86 | KCNH2 (0.56) | KCNH2NPY1RBRD4PRKDCGAA | |
| SCHEMBL961779 | 0.85 | NPY1R (0.65) | KCNH2NPY1R | |
| SCHEMBL7019934 | 0.83 | NPY1R (0.61) | KCNH2NPY1R | |
| SCHEMBL7015881 | 0.82 | KCNH2 (0.51) | KCNH2NPY1RBRD4PRKDC | |
| SCHEMBL7018612 | 0.81 | KCNH2 (0.49) | KCNH2NPY1RBRD4PRKDC | |
| SCHEMBL961537 | 0.81 | KCNH2 (0.51) | KCNH2NPY1RBRD4PRKDCCNR2 | |
| SCHEMBL961535 | 0.81 | KCNH2 (0.51) | KCNH2NPY1RBRD4PRKDCCNR2 | |
| SCHEMBL7016153 | 0.81 | KCNH2 (0.48) | KCNH2NPY1RBRD4PRKDCGAA | |
| SCHEMBL12946506 | 0.81 | KCNH2 (0.48) | KCNH2NPY1RBRD4PRKDCGAA | |
| SCHEMBL7016743 | 0.81 | KCNH2 (0.48) | KCNH2NPY1RBRD4PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2264026-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | NPY4R, NPY1R, NPY2R | KCNH2 1295/4885NPY1R 2/4885BRD4 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.